Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu
Pharmaceutical Co., Inc., today announced that it has submitted to the
U.S. Food & Drug Administration a New Drug Application (NDA) seeking
approval to market low-dose mesylate salt of paroxetine (LDMP) for the
treatment of vasomotor symptoms associated with menopause.
In March 2012, Noven announced completion of the LDMP clinical
development program, which included two Phase 3 studies involving an
aggregate of 1,180 subjects from more than 130 centers across the U.S.
Phase 3 study results for LDMP are scheduled to be presented at the
North American Menopause Society Annual Meeting in October 2012.
"The submission of the LDMP New Drug Application for consideration by
the FDA represents a significant step toward our goal of offering a
low-dose non-hormonal therapeutic option for the treatment of menopausal
hot flashes," said Joel S. Lippman, M.D., Noven's Executive Vice
President - Product Development and Chief Medical Officer.